Author + information
- Pamela Morris,
- Narinder Bhalla,
- Kellie Mclain,
- Hector Malave,
- James Underberg,
- Ralph Joe Teague,
- Hollye Garner,
- Deborah Winegar and
- Ray Pourfarzib
Many subjects with relatively normal levels of LDL cholesterol have increased numbers of atherogenic lipoproteins, hence exhibiting discordance. There are few data comparing the relationship between an individual's LDL-P and Apo B levels and whether discordance exists between these values.
To determine the relationship between LDL-P and Apo B and to determine the heterogeneity of LDL-P at Apo B levels less than 78 mg/dL (a value at the 20th percentile in the Framingham Offspring Population).
Data were derived from a group of consecutive patients added to a large, single laboratory database (LipoScience, Inc., Raleigh, NC) between December 29, 2010 and January 5, 2011 in which standard lipid chemistry (LDL- and HDL-cholesterol and triglycerides), Apo B, and NMR lipoprotein profile data were available. Subjects were assigned to LDL-P categories using cut-points corresponding to the percentiles of the Framingham Offspring Study.
The cohort consisted of 1,196 subjects. Mean subject age was 58+14 years (46% female), mean Apo B concentration 97 mg/dL, and mean LDL-P concentration 1,574 nmol/L. Apo B and LDL-P levels were highly correlated (r=0.8421) but often discordant. Of those with an Apo B concentration of < 78 mg/dL (n=268), only 64% had LDL-P concentrations of <1100 nmol/L (20th Framingham percentile) whereas 28% had LDL-P levels of 1100-1299 nmol/L (20th – 40th Framingham percentile) and 8% had LDL-P >1300 nmol/L (>40th Framingham percentile).
Although many subjects in the analysis had concordant levels of Apo B and LDL-P, a considerable percentage had much higher LDL-P levels despite attainment of an Apo B level of <78 mg/dL. These patients retain considerable potential LDL-attributable coronary heart disease risk, with 36% of them having an LDL-P concentration greater than 1100 nmol/L.
Poster Sessions, Expo North
Saturday, March 09, 2013, 3:45 p.m.-4:30 p.m.
Session Title: Prevention: Lipoproteins, Particles and Ratios
Abstract Category: 24. Prevention: Clinical
Presentation Number: 1145-6
- 2013 American College of Cardiology Foundation